'The Pazdur Effect': A Tale Of Three US FDA Oncology Advisory Committee Meetings
Executive Summary
ODAC meetings are usually few and far between – and rarely come with good news for the sponsor. Below are some lessons learned from the bounty (three!) held this week.
You may also be interested in...
‘The Gruber Moment’: How CBER Got The Answers It Wanted On COVID Vaccine Guidance
As US FDA recovers from aducanumab and looks towards an advisory committee on Pfizer’s COVID vaccine, it’s worth reflecting on how Office of Vaccine Research & Review Director Marion Gruber created positive turning points for the agency during a general discussion of vaccine approval standards at the VRBPAC.
Accelerated Approval Under Review By US FDA: Completing Confirmatory Trials A Focus
Top officials want confirmatory trials to finish in a ‘reasonable amount of time’ and worry that ‘if 100% of them were able to confirm, then the bar’s too high.’
Cures II Wish List: Reconsidering Accelerated Approval?
Richard Pazdur wants the oncology community to take a fresh look at US FDA’s expedited review programs. One big question: should there be fewer of them?